KANE BIOTECH INC (KNE.CA) Stock Price, Forecast & Analysis
Canada • TSX Venture Exchange • TSX-V:KNE • CA4838092084
KNE.CA Key Statistics, Chart & Performance
The current stock price of KNE.CA is 0.04 CAD. In the past year, price decreased by -63.64%.
KNE.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KNE.CA. When comparing the yearly performance of all stocks, KNE.CA is a bad performer in the overall market: 89.83% of all stocks are doing better.
KNE.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KNE.CA. Both the profitability and financial health of KNE.CA have multiple concerns.
KNE.CA Financial Highlights
Over the last trailing twelve months KNE.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -503.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KNE.CA Forecast & Estimates
KNE.CA Ownership
About KNE.CA
Company Profile
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The Company’s segments include Animal health, and Human health. The company has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
Company Info
KANE BIOTECH INC
290-100 Innovation Drive
Winnipeg MANITOBA R3T 2N2 CA
CEO: Marc Edwards
Employees: 0
Phone: 12044531301
KANE BIOTECH INC / KNE.CA FAQ
What does KNE do?
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The Company’s segments include Animal health, and Human health. The company has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
What is the stock price of KANE BIOTECH INC today?
The current stock price of KNE.CA is 0.04 CAD.
What is the dividend status of KANE BIOTECH INC?
KNE.CA does not pay a dividend.
What is the ChartMill rating of KANE BIOTECH INC stock?
KNE.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the number of employees for KANE BIOTECH INC?
KANE BIOTECH INC (KNE.CA) currently has 0 employees.
What is the market capitalization of KNE stock?
KANE BIOTECH INC (KNE.CA) has a market capitalization of 6.69M CAD. This makes KNE.CA a Nano Cap stock.